Influenza and Emerging Infectious Diseases

About Conference

Scientific Sessions

Market Analysis Report

Infectious Disease Therapeutics Market (drugs & vaccine) was valued at US$ 105.13 Billion in 2018 and expected to reach USD 179.70 Billion by the end of 2025 with a growing potential of 7.96 %.

Top 6 Infectious Diseases (HIV, malaria, hepatitis, influenza, Human Papillomavirus (HPV), and tuberculosis) therapeutics market worth $86.2 Billion By 2025

The global Influenza therapeutics market was valued USD 1699.7 Million in 2016, and is estimated to reach US$ 2012.6 Million by 2025, with a growth potential of 1.4% 

Major factors those are driving the growth of the market:

• Increasing the occurrence of infectious diseases
• Growing use of direct acting anti-viral
• Increasing healthcare expenditure
• Increasing geriatric population,
• Growing healthcare awareness
• Increasing government funding’s in developing countries.
• The major factor restraining the growth of the market is generic erosion, Patent expiration of infectious disease drugs.

Regional wise Infectious disease Therapeutics Market

• North America: USA & Canada
• Europe: Germany, UK, France, Spain, Italy, Nordic countries, Benelux, Poland & Russia
• Asia Pacific: China, India, Japan, ASEAN, Australia, and New Zealand
• Latin America: Brazil & Mexico
• Middle East & Africa: GCC, Southern Africa, North Africa

Therapeutics

• Anti-infective drugs: Antibacterial, antifungal, antiparasitic, and antiviral drugs are some of the anti-infective drugs used for the treatment of infectious diseases.
• Vaccines

End users:

• Pediatrics
• Adolescence
• Adults
• Elderly

Disease type therapeutics market  

HIV

• Emtriva
• Aptivus
• Isentress
• Lexiva/Telzir
• Selzentry
• Tivicay
• Atripla
• Complera
• Genvoya
• Odefsey
• Stribild
• Truvada
• Triumeq
• Descovy
• Vitekta

Influenza

• Relenza
• Tamiflu
• Rapivab

TB

• Sirturo

Malaria

• Coartem

HPV

Hepatitis

Key Players of Infectious disease Therapeutics Market

• Abbott Laboratories
• AbbVie, Astellas Pharma
• Achillion Pharmaceuticals
• Astrazeneca PLC
• AstraZeneca, Auritec Pharmaceuticals
• Bayer
• Biocryst Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Chimerix Pharmaceuticals
• Chiron Corporation
• CSL Limited
• Cubist, Eli Lilly
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann-La Roche AG
• Gilead Sciences
• Gilead Sciences, Inc.
• Glaxosmithkline PLC
• Isis Pharmaceuticals
• Janssen Pharmaceutical
• Johnson & Johnson
• Pfizer
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Nanotherapeutics Inc.
• Novartis International AG
• Protein Sciences Corporation
• pSivida
• Roche Holding AG
• Sanofi SA
• Shionogi & Co. Ltd.
• Sinovac Biotech Ltd.

Reference:

• Centers for Disease Controle and Prevention
• National Institute of Allergy and Infectious Diseases
• Infectious Diseases Society of America
• Business Wire
• Research and Markets
• Future Market Insights
• Credence Research
• Yahoo finance
• Industry Experts Inc.
• BCC Research
• PR Newswire Association LLC
• Report Buyer
• Market Data Forecast
• Grand View Research, Inc.
• Transparency Market Research
• Persistence Market Research
• Coherent Market Insights
• Influenza Research Database
• Influenza Reagent Resource
• BEI Resources
• ATCC

Visa Information

 

Issue with VISA!!

Are you planning to have a professional and delightful trip to Toronto, Canada???

We believe you must be having a query regarding your Visa to Visit as a Speaker/Delegate, Tourist or Business Person at Toronto, Canada. Influenza Research Committee will be happy to help you in all regards to plan your trip to Toronto, Canada. Here is the simplest way to know the process for your Visa Approval. Kindly drop us an email at . Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA. Processing time for visa applications vary depending on the office and the time of the year. Delegates/Attendees are encouraged to submit their visa applications well in advance of the date of the event at a Visa Application Centre or on-line E-applications, including all supporting documents.

 

Past Conference Report

Flu-2016

Conference series llc LTD hosted the “2^nd International Conference on Flu” during October 31-November 02, 2016 at DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, USA with the theme “Scientific Milestones in Understanding and Preventing Flu” where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.

Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Virologists, scientists, researchers, students and leaders in Flu Research, who made this event successful.

The Conference was carried out through various informative and cutting edge sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

• Flu Vaccines: Current and Novel Approach
• Pathology of Influenza Virus Infections
• Flu Symptoms & Treatment
• Antivirals and Therapeutics
• Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups
• Flu Virus -Advancements in Detection & Differentiation
• Flu: Immunology & Genetics
• Flu Clinical Studies & Case Reports
• Epidemiology and Public Health of Influenza
• Surveillance Issues and Burden of Disease

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

Notable Keynotes:

• Donald P Francis, Global Solutions for Infectious Diseases, USA
• Ananda M Chakrabarty, University of Illinois College of Medicine, USA
• Anthony S Gilbert, hVIVO, UK
• Palayakotai Raghavan, Nanorx Inc, USA
• Manon M J Cox, Protein Sciences, USA
• Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA
• Sunil K Lal, Monash University, Malaysia

All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Jun Wang, University of Arizona, USA and Sunil K Lal, Monash University, Malaysia for his remarkable contribution towards smooth functioning at Flu-2016 Conference.

Conference Sessions Chairs:      

• Donald P Francis, Global Solutions for Infectious Diseases, USA
• Palayakotai Raghavan, Nanorx Inc, USA
• Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA

For further information visit : Flu 2016

Conference Series llc LTD offers its heartfelt appreciation to Societies and Organizations includes Allied Academies, Andrew John Publishing Inc., New York Private Equity Forums and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series llc LTD in supporting and making the conference a never before one.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph Flu-2016, Conference Series llc LTD is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, "3^rd International Conference on Flu & Emerging Infectious Diseases" to be held during September 17-18, 2018 at San Diego, USA.

Let us meet again @ Flu-2018

Past Reports  Gallery